Novo Nordisk A/S $NOVO-B.CO has overtaken SAP SE $SAP to regain its position as the most valuable publicly traded company in Europe. The Danish pharmaceutical giant's market capitalization rose to $365 billion as of 10:20 a.m. in Copenhagen, narrowly surpassing SAP’s $364.3 billion valuation. The resurgence in share price—up as much as 2.3% on Friday—followed an announcement that Novo will advance its experimental obesity drug, amycretin, to late-stage clinical development. The decision came after favorable feedback from global health regulators, boosting investor confidence in Novo’s future growth pipeline.